Bruges canals in the Benelux region, a strategic market for the Ferrer group's distribution and international presence.

Global presence

Ferrer Benelux

Present since 2001

Ferrer team smiling in a tunnel with street art, wearing company corporate t-shirts.

Ferrer Benelux understands pharmaceutical activity as an opportunity to contribute to real social change, integrating social and environmental impact into business decision-making.

We operate with a long-term sustainability approach, seeking a balance between economic viability and the generation of value for society. This model allows us to advance in initiatives that reinforce both the well-being of people and the development of our team and our environment.

Interventional cardiology

For use during percutaneous coronary interventions (PCI), Ferrer Benelux offers an immediate-acting and reversible platelet aggregation inhibitor for intravenous applications.

Find out more

Cardiology

For the secondary prevention of cardiovascular diseases, Ferrer Benelux offers a fixed-dose combination. It helps prevent blood clots, lower cholesterol, and lower blood pressure, offering a comprehensive approach to reducing the risk of heart attacks, strokes, and other cardiovascular events.

Find out more

Pulmonary vascular and interstitial diseases

Ferrer Benelux is known for its contribution in the field of treatment of pulmonary arterial hypertension (PAH). The drug that Ferrer Benelux markets for the treatment of PAH works by dilating the blood vessels in the lungs, improving exercise capacity and slowing down the progression of the disease.

The drug may be given by continuous subcutaneous or intravenous infusion.

Find out more